Skip to content
Prostate Cancer Radiation Therapy
Radiation Oncology

Prostate Cancer Radiation Therapy

About This Department

 
Radiation Oncology and Urology

Fifteen years after diagnosis, 97 in 100 men were alive of their prostate cancer whether they chose radiotherapy, surgery or monitoring. The decision turns on what each path costs you.

That finding comes from the ProtecT trial, which randomized 1,643 men in the United Kingdom and followed them for a median of 15 years. Radiotherapy for prostate cancer has changed more in the last decade than in the thirty years before it. A course that took seven and a half weeks now takes four, and for some men five sessions, and the trials behind each of those choices are set out below. Send us your PSA history, biopsy report and MRI, and a radiation oncologist will tell you which course fits your cancer and how long you would need in Istanbul.

2.9%
Prostate cancer deaths at 15 years after radiotherapy in ProtecT
20
Sessions in the modern standard course, down from 37
95.8%
Relapse-free at five years after five-session SBRT
Free
Review of your PSA, biopsy and MRI
Free consultation

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

The three paths in the ProtecT trial after a median of 15 years, 1,643 men, New England Journal of Medicine 2023
  Active monitoring Surgery Radiotherapy
Died of prostate cancer 3.1 percent 2.2 percent 2.9 percent
Died of any cause About one in five in every group    
Developed metastases 9.4 percent 4.7 percent 5.0 percent
Started long-term hormone therapy 12.7 percent 7.2 percent 7.7 percent
Alive with no treatment at all 24.4 percent    
Radiotherapy in the trial     37 sessions with six months of hormone therapy, an older schedule than today's

No other common cancer offers three good answers to the question of what to do next, and the table gives the long-term result of each. The trial authors' own conclusion was that choosing a treatment means weighing the benefits against the harms of each path. Men choose radiotherapy over surgery for reasons that have little to do with cure rates.

  • No anesthetic, no operation and no catheter for a week afterward. Men with heart or lung disease, or on blood thinners, are often steered toward it for that reason.
  • Urinary leakage is uncommon after radiotherapy and common in the first year after surgery.
  • Erections decline more gradually and less often, though hormone therapy, when added, removes the difference for as long as it lasts.
  • It treats cancer that has already crept beyond the capsule of the gland, which a surgeon cannot always remove cleanly.
  • Against that, bowel symptoms are more frequent after radiotherapy, the PSA falls slowly over one to two years and a rise later is harder to interpret, and a man who wants his prostate out for peace of mind will not get that here.
Know your risk group
Three numbers place you. They are the PSA level, the Gleason score or grade group from the biopsy, and the stage from examination and MRI. Low, intermediate and high risk each carry a different course and a different decision about hormones.
Hear both specialists
A urologist and a radiation oncologist should each explain what they would do and what it would cost you in side effects. A tumor board does this in one meeting, and the free remote review is a first pass at it.
Choose the course, then the calendar
Once radiotherapy is the plan, the number of sessions and whether hormones are added follow from the risk group, and the weeks in Istanbul follow from the sessions.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

What radiotherapy for prostate cancer usually involves, by risk group
Risk group Typical definition Course Hormone therapy
Low PSA under 10, grade group 1, small tumor Active monitoring is a full alternative. When treatment is chosen, 20 sessions or five stereotactic sessions. None
Intermediate PSA 10 to 20, or grade group 2 or 3 20 sessions, or five stereotactic sessions for favorable cases Four to six months for most, none for the most favorable
High PSA above 20, grade group 4 or 5, or tumor through the capsule 20 or more sessions to the prostate, sometimes with the pelvic lymph nodes, or external beam plus a brachytherapy boost Eighteen months to three years
After surgery, PSA rising Cancer left behind or returning at the surgical bed 33 to 35 sessions to the prostate bed Often six months

Which course, and how many sessions

For thirty years the standard ran to 37 or 39 daily sessions over seven and a half weeks. Two large trials have since shortened it. Both rest on one observation, namely that prostate cancer cells are unusually sensitive to the size of each daily dose, so fewer and larger doses hurt the tumor more than they hurt the bladder and bowel around it.

Five years after treatment, 90.6 percent of men given 20 sessions over four weeks were free of relapse, against 88.3 percent of men given 37 sessions over seven and a half weeks. Side effects were the same.
CHHiP trial, 3,216 men at 71 centers, Lancet Oncology 2016

Twenty became the standard. Then came five.

CHHiP settled the first. PACE-B then tested five. It randomized 874 men with low or intermediate-risk disease to five sessions of stereotactic radiotherapy over one to two weeks or to a conventional course of 20 or 39. At five years, 95.8 percent of the SBRT group and 94.6 percent of the conventional group were free of relapse. Long-term urinary side effects of grade 2 or worse were more frequent after five sessions, 26.9 against 18.3 percent, and bowel effects were the same in both groups.

  • 20 sessions over four weeks. The standard course for most men at every risk level, and the one against which the others are measured.
  • Five stereotactic sessions over one to two weeks. For low and intermediate-risk disease in men without severe urinary symptoms. The shortest stay abroad.
  • Brachytherapy. Radioactive seeds placed permanently, or temporary high-dose wires, delivered under anesthetic in one or two visits, alone for low-risk disease or as a boost to external beam treatment for high-risk disease.
  • 33 to 39 sessions. Still used for the prostate bed after surgery and for some men treated with the lymph nodes.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

The courses compared
  20 sessions 5 sessions 37 to 39 sessions
Weeks of treatment 4 1 to 2 7.5 to 8
Trial evidence CHHiP, non-inferior to 37 sessions PACE-B, non-inferior to 20 or 39 sessions The older standard both trials were measured against
Who it suits Nearly everyone Low and intermediate risk, good urinary function, prostate not very large After surgery, some high-risk cases
Late urinary effects, grade 2 or worse 11.7 percent at five years in CHHiP 26.9 percent at five years in PACE-B 9.1 percent at five years in CHHiP
Late bowel effects, grade 2 or worse 11.9 percent 10.7 percent 13.7 percent
  1. Staging. A prostate MRI if not already done, and for high-risk disease a PSMA PET-CT, which finds spread that older scans miss and can change the plan entirely.
  2. Markers and spacer. Three gold seeds may be placed in the prostate under ultrasound so the machine can see the gland each day. A hydrogel spacer injected between prostate and rectum pushes the bowel a centimeter out of the high-dose zone. Both take a short outpatient visit, one to two weeks before planning.
  3. Bladder and bowel routine. From the planning scan on, you attend each session with a comfortably full bladder and an empty rectum, because the prostate moves with both. The routine is taught once and repeated every day.
  4. Planning CT in the treatment position, fused with the MRI, then five to seven working days of contouring, planning and physics checks.
Tell us before planning starts
Severe urinary symptoms or a very large prostate, which favor a longer course over five sessions. Earlier prostate surgery for benign enlargement. Inflammatory bowel disease, which raises the risk of bowel damage. A hip replacement, which affects imaging and planning. A pacemaker. Blood thinners, if markers or a spacer are planned. Every medicine you take, including anything for erections.
How the four-month hormone course was proven, and who does not need it
RTOG 94-08 randomized 1,979 men with early prostate cancer to radiotherapy alone or radiotherapy with four months of hormone therapy starting two months before it. Ten-year survival was 62 percent with hormones and 57 percent without, and deaths from prostate cancer fell from 8 to 4 percent. The benefit appeared in men with intermediate-risk disease and not in men with low-risk disease, who should not be given hormones for a gain the trial could not find. The results were published in the New England Journal of Medicine in 2011.

What does hormone therapy add, and what does it take?

Prostate cancer grows on testosterone. Remove the fuel and the fire dims. Injections that switch off the testicles' production of it, given every one to six months, shrink the gland before radiotherapy and starve the cancer cells that the beam damages. Four to six months suffice for intermediate-risk men. For high-risk men the courses run 18 months to three years, and it is the hormones, more than the radiotherapy, that dominate the experience of treatment. Hot flushes, tiredness, loss of libido and erections, weight gain, loss of muscle, tender breasts and a low mood are the common effects, and over years the drugs thin bone and raise the risk of diabetes and heart disease. Some high-risk men also receive newer hormone tablets. Newer trials are testing whether the courses can be shorter still, and the answer differs by risk group. A man who is told he needs hormones should ask three things, namely for how long, on which trial evidence, and whether his risk group could be treated without them, because a year of injections given to a man who did not need them is the most avoidable harm in the whole of prostate cancer care.

Ask. The answer should come with a trial name.

What are the side effects, and how has technique changed them?

Late bowel side effects of grade 2 or worse occurred in 6.4 percent of men with intensity-modulated radiotherapy and 21.7 percent with older three-dimensional planning. Late bladder effects occurred in 3.7 against 12.3 percent. Cure rates were identical.
Randomized trial of 215 men, Cancer 2016

Because of that trial, a patient should ask which technique a unit uses. Modulated radiotherapy, delivered today as VMAT arcs with a cone-beam CT before every session, wraps the dose around the prostate and holds it away from the rectum and bladder in a way that older planning could not. The rest follows, organ by organ.

Bowel

Loose stools, urgency and passing mucus begin in the second or third week and settle within a month of finishing. Diet helps a little. A spacer helps more. One man in ten in the modern trials has lasting changes, rectal bleeding from fragile vessels above all that is more alarming than dangerous and is treated through a flexible scope if it persists. Anyone with a colonoscopy due should have it before radiotherapy rather than after, because a biopsy or polyp removal from an irradiated rectum heals poorly and endoscopists avoid it for years afterward.

Bladder

Frequency, urgency, burning and getting up at night build over the course and peak in the last week. Tamsulosin and drinking well through the day help. Lasting urinary effects of grade 2 or worse affected one man in ten after 20 sessions and one in four after five sessions in the trials above. Men who begin with a weak stream do worse. Units therefore score urinary symptoms before choosing the course.

Erections and fertility

Erections weaken slowly.

Over two to five years after radiotherapy the blood vessels that supply them scar. Half of the men who function well beforehand keep function at five years without help, tablets help most of the rest, and hormone therapy suspends both desire and function for as long as it is given and for some months after. Ejaculate becomes scant or dry. Assume fertility lost, and bank sperm beforehand if it matters.


Get help the same day
Being unable to pass urine at all. Heavy rectal bleeding. Fever with pain on passing urine. Severe pain in the pelvis. During the course, tell the treatment team. Once home, go to a local emergency department and show them the treatment summary.

Late risks measured in years

A second cancer of the bladder or rectum caused by the radiation is a small risk that grows with time and matters most to men under 60. Narrowing of the urethra occurs in a few percent, more after a previous prostate operation. Both come up at consent, with the numbers for your plan.

Weeks in Istanbul

Plan on the course plus two weeks.

A 20-session course means five to six weeks in the city, a five-session course means three, and a course with markers or a spacer adds a week at the start because the tissues have to settle before planning. Hormone injections can begin at home two months earlier and continue at home afterward. Radiotherapy alone sets the stay. You can fly the day after the last session.

What decides the cost?

Session count decides less than patients expect. Planning and physics take the same effort for five sessions as for twenty, and a stereotactic plan takes more. The technique named in writing, daily cone-beam imaging, markers and their placement, a hydrogel spacer, the PSMA PET-CT and the prostate MRI, brachytherapy where it is used, and hormone injections are each separate items, and a quote should say which of them it contains. Hotel nights for two people over five or six weeks form a large share of what a family spends on a 20-session course and a small share on a five-session course. Your own health moves the figure, since blood thinners, a pacemaker, diabetes and a previous prostate operation add checks and consultations, and a man on long-term hormone therapy needs a bone density scan and a cardiology review that a man without it does not.

Packages published by hospitals in Istanbul for prostate radiotherapy are sold by session count, most often 30 to 35 sessions, with consultation, interpreter and transfers included and hotel nights sometimes added. Ask why the package is longer than the 20 sessions that CHHiP made standard, and whether a 20-session or five-session course is offered at a lower figure.

Your own figure follows the free review of your file.

What about language, companions and follow-up at home?

One coordinator from the international patients team is assigned from your first message and stays with you to the last session. The team works in English, Arabic, French, Russian, Serbian, Romanian and Spanish and arranges interpreting in other languages on request, and an interpreter attends the consultation and consent. An invitation letter naming the hospital and the treating doctor is sent about ten days before travel. The international patients office arranges the airport transfer, a hotel or apartment for you and a companion, and the daily ride to the hospital, and for a course of five or six weeks an apartment near the hospital suits most couples better than a hotel. Nobody is admitted for this treatment. Should you be admitted for any other reason, the room has a companion bed. Halal, vegetarian and diabetic meals are available, and a prayer room is on site. Urology, radiation oncology and medical oncology share one hospital, so a change of plan at the tumor board does not mean a change of address.

Back home, the coordinator stays reachable on the same WhatsApp number, and your PSA results can be sent to the treating oncologist. The first PSA is checked three months after the end and then every six months. It falls slowly after radiotherapy, over one to two years. A small rise and fall in the second year, called a bounce, is common. It does not mean relapse. The treatment summary you leave with lists every dose to the prostate, the rectum, the bladder and the femoral heads, and any doctor who treats you later, for this cancer or for another, will plan around the numbers in it, so keep it with your passport.

Prostate cancer radiation therapy FAQ

Is radiation as effective as surgery for prostate cancer?
In the ProtecT trial, deaths from prostate cancer at 15 years were 2.9 percent after radiotherapy and 2.2 percent after surgery, a difference that was not statistically significant. Metastases were 5.0 and 4.7 percent. The two paths differ mainly in their side effects.
How many radiotherapy sessions does prostate cancer need?
Twenty sessions over four weeks is the modern standard, proven non-inferior to 37 sessions in the CHHiP trial. Five stereotactic sessions over one to two weeks matched a conventional course in the PACE-B trial for low and intermediate-risk disease, with more lasting urinary side effects.
Do I need hormone therapy with radiotherapy?
Not for low-risk disease, where a trial of 1,979 men found no benefit. For intermediate-risk disease four to six months improved survival, and for high-risk disease the courses run 18 months to three years.
How long do I need to stay in Istanbul?
About three weeks for a five-session course and five to six weeks for a 20-session course, including consultation, planning and the sessions. You can fly the day after the last one.
Will radiotherapy affect my erections?
Function declines gradually over two to five years in about half of men who function well beforehand, and tablets help most of the rest. Hormone therapy suspends function while it is given.
Can my wife come with me?
Yes. The international patients office arranges a hotel or apartment for you both for the whole course, and rooms for admitted patients have a companion bed.

References

  1. Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine. 2023;388(17):1547-1558.
  2. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncology. 2016;17(8):1047-1060.
  3. van As N, Griffin C, Tree A, et al. Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer. New England Journal of Medicine. 2024;391(15):1413-1425.
  4. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. New England Journal of Medicine. 2011;365(2):107-118.
  5. Viani GA, Viana BS, Martin JE, Rossi BT, Zuliani G, Stefano EJ. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial. Cancer. 2016;122(13):2004-2011.

Editor's note

Written by the Biruni Hospital medical editorial team. Reviewed by Prof. Dr. Özcan YILDIZ, Medical Oncology.

Related Treatments

View All